IQVIA has collaborated with Friends of Cancer Research to advance the use of real-world evidence (RWE) in clinical trials to better understand treatment outcomes over time.
According to IQVIA, the research will ascertain whether clinical benefits observed for treatments in clinical trials match with the benefits of the therapies in real-world settings.
RWE uses dynamic data and other assets like EMR, hospital, pharmacy, and claims sources. The research also uses genomics, mobile health, and patient-reported outcomes.
This project is part of the Friends of Cancer Research initiative that works towards demonstrating the application of RWE in cancer research.
A recent study as part of the project saw six US research centres follow protocol to evaluate real-world endpoints in cancer patients. This included time to next treatment, overall survival, time to treatment discontinuation, progression-free survival and time to progression.
The results were published in the JCO Clinical Cancer Informatics and were titled ‘An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer’.
IQVIA Real-World Solutions chief scientific officer Nancy Dreyer said: “While randomised clinical trials are the gold standard to evaluate whether a medical treatment can work, they don’t determine if treatment works for diverse patients outside the clinical setting and within real-world situations.
“IQVIA is excited to be part of this initiative. This important study demonstrates the value of real-world evidence to measure and quantify the comparative benefits and risks of various medical products.”
Non-identified patient data from administrative claims and electronic health records were used to evaluate real-world endpoints and the researchers found that the results were consistent with results obtained from randomised clinical trials.